Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells

2005 ◽  
Vol 75A (1) ◽  
pp. 210-215 ◽  
Author(s):  
Hidetsugu Tsujigiwa ◽  
Hitoshi Nagatsuka ◽  
Mehmet Gunduz ◽  
Andrea Rodriguez ◽  
Rosario S. Rivera ◽  
...  
Keyword(s):  
Bone Morphogenetic Protein ◽  
Human Bone ◽  
Bone Morphogenetic Protein 2 ◽  
Type I ◽  
Cellular Activity ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Recombinant Human Bone

Osteoinduction by Recombinant Human Bone Morphogenetic Protein-2 in Muscles of Non-Human Primates

2002 ◽  
Vol 30 (3) ◽  
pp. 251-259 ◽  
Author(s):  
K Kusumoto ◽  
K Bessho ◽  
K Fujimura ◽  
J Akioka ◽  
Y Okubo ◽  
...  
Keyword(s):  
Bone Morphogenetic Protein ◽  
Type I Collagen ◽  
Human Bone ◽  
Bone Morphogenetic Protein 2 ◽  
Placebo Control ◽  
Type I ◽  
Group I ◽  
Morphogenetic Protein ◽  
Human Bone Morphogenetic Protein ◽  
Recombinant Human Bone

Heterotopic osteoinduction in a muscle of a medium-sized, non-human primate (Japanese macaque monkey; Macaca fuscata) was investigated with recombinant human bone morphogenetic protein-2 (rhBMP-2) mixed with atelopeptide type I collagen as the carrier. Nine monkeys were divided into three groups of three: groups I (1.25 mg rhBMP-2), II (250 μg rhBMP-2) and III (50 μg rhBMP-2). Four weeks after implanting into the calf muscle pouch, the implant was examined radiographically and histologically. In one specimen of three in group I, marked radio-opaque shadow, massive chondrogenesis and partial osteogenesis were observed. In the other two specimens, only microscopic calcification signs were recognized. In groups II and III, no findings of heterotopic osteoinduction were radiographically observed; however, nuclei from muscle bundles reacted to rhBMP-2 and were large and round, as in muscle bundles near the site of osteogenesis in group I. A positive control study using rats was carried out in parallel. This was a dose-finding study, with the monkeys in group III acting as a sub-effective dose (placebo) control, and rats acting as an active control, or verum, to show that the techniques are sufficiently sensitive. Bone morphogenetic protein appears to osteoinduce less bony material in soft tissue in primates than in rats.

Sign in / Sign up

Export Citation Format

Share Document